

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number
WO 01/49678 A1

(51) International Patent Classification⁷: C07D 403/02,
403/14, 413/14, 405/14, 471/04, A61K 31/496, 31/5377,
A61P 25/00

Ejner, Knud [DK/DK]; Toftekærsvæj 29, DK-2820 Gentofte (DK).

(21) International Application Number: PCT/DK00/00721

(74) Common Representative: H. LUNDBECK A/S; John
Meidahl Petersen, Ottiliavej 9, DK-2500 Valby-Copen-
hagen (DK).

(22) International Filing Date:
20 December 2000 (20.12.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility
model), DK, DK (utility model), DM, DZ, EE, EE (utility
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK
(utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 1999 01885 30 December 1999 (30.12.1999) DK

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): H.
LUNDBECK A/S [DK/DK]; John Meidahl Petersen,
Ottiliavej 9, DK-2500 Valby-Copenhagen (DK).

Published:


— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (for US only): RUHLAND,
Thomas [DE/DK]; Østergaards Alle 16, DK-2500 Valby
(DK). KROG-JENSEN, Christian [SE/DK]; Hornemanns-
gade 23, DK-2100 Copenhagen (DK). ROTTLÄNDER,
Mario [DE/DK]; Harrestrupvang 3c, 2th, DK-2500 Valby
(DK). MIKKELSEN, Gitte [DK/DK]; Eskebjerggård 34,
4tv, DK-2760 Måløv (DK). ANDERSEN, Kim [DK/DK];
Ringerbakken 22, DK-2830 Virum (DK). MOLTZEN,
Ringerbakken 22, DK-2830 Virum (DK).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE



(57) Abstract: The present invention provides compounds of
formula (I): wherein R¹-R⁸, X, Y, Z, n and m are defined in the
application. The compounds of the invention have affinity for
the 5-HT_{1A} receptor.

Substituted phenyl-piperazine derivatives, their preparation and use

The present invention relates to novel substituted phenyl-piperazine derivatives potently binding to the 5-HT_{1A} receptor, pharmaceutical compositions containing these compounds and the use thereof for the treatment of certain psychiatric and neurological disorders. Many of the compounds of the invention are also potent serotonin reuptake inhibitors and/or D₃/D₄ ligands and are thus considered to be particularly useful for the treatment of depression and psychosis.

10 Background Art

Clinical and pharmacological studies have shown that 5-HT_{1A} agonists and partial agonists are useful in the treatment of a range of affective disorders such as generalised anxiety disorder, panic disorder, obsessive compulsive disorder, depression and aggression.

15

It has also been reported that 5-HT_{1A} ligands may be useful in the treatment of ischaemia.

An overview of 5-HT_{1A} antagonists and proposed potential therapeutic targets for these antagonists based upon preclinical and clinical data are presented by Schechter et al.,

20 *Serotonin*, 1997, Vol.2, Issue 7. It is stated that 5-HT_{1A} antagonists may be useful in the treatment of schizophrenia, senile dementia, dementia associated with Alzheimer's disease, and in combination with SSRI antidepressants also to be useful in the treatment of depression.

25 5-HT reuptake inhibitors are well known antidepressant drugs and useful for the treatment of panic disorders and social phobia.

The effect of combined administration of a compound that inhibits serotonin reuptake and a 5-HT_{1A} receptor antagonist has been evaluated in several studies (Innis, R.B. et al., *Eur. J.*

30 *Pharmacol.*, 1987, 143, p 195-204 and Gartside, S.E., *Br. J. Pharmacol.* 1995, 115, p 1064-1070, Blier, P. et al, *Trends Pharmacol. Sci.* 1994, 15, 220). In these studies, it was found that combined 5-HT_{1A} receptor antagonists and serotonin reuptake inhibitors would produce a more rapid onset of therapeutic action.

Dopamine D₄ receptors belong to the dopamine D₂ subfamily of receptors, which is considered to be responsible for the antipsychotic effects of neuroleptics. The side effects of neuroleptic drugs, which primarily exert their effect via antagonism of D₂ receptors, are known to be due to D₂ receptor antagonism in the striatal regions of the brain. However,

5 dopamine D₄ receptors are primarily located in areas of the brain other than striatum, suggesting that antagonists of the dopamine D₄ receptor will be devoid of extrapyramidal side effects. This is illustrated by the antipsychotic clozapine, which exerts higher affinity for D₄ than D₂ receptors, and is lacking extrapyramidal side effects (Van Tol et al. *Nature* 1991, 350, 610; Hadley *Medicinal Research Reviews* 1996, 16, 507-526 and Sanner *Exp.*

10 *Opin. Ther. Patents* 1998, 8, 383-393).

A number of D₄ ligands, which were postulated to be selective D₄ receptor antagonists (L-745,879 and U-101958) have been shown to possess antipsychotic potential (Mansbach et al. *Psychopharmacology* 1998, 135, 194-200). However, recently it has been reported that

15 these compounds are partial D₄ receptor agonists in various *in vitro* efficacy assays (Gazi et al. *Br. J. Pharmacol.* 1998, 124, 889-896 and Gazi et al. *Br. J. Pharmacol.* 1999, 128, 613-620). Furthermore, it has been shown that clozapine, which is an effective antipsychotic, is a silent antagonist (Gazi et al. *Br. J. Pharmacol.* 1999, 128, 613-620).

20 Consequently, D₄ ligands, which are partial D₄ receptor agonists or antagonists, may have beneficial effects against psychoses.

Dopamine D₄ antagonists may also be useful for the treatment of cognitive deficits (Jentsch et al. *Psychopharmacology* 1999, 142, 78-84).

25 It has also been suggested that dopamine D₄ antagonists may be useful to reduce dyskinesia occurring as a result of the treatment of Parkinson's disease with L-dopa (Tahar et al. *Eur. J. Pharmacol.* 2000, 399, 183-186).

30 Dopamine D₃ receptors also belong to the dopamine D₂ subfamily of receptors, and they are preferentially located in limbic regions of the brain (Sokoloff et al. *Nature*, 1990, 347, 146-151), such as the nucleus accumbens, where dopamine receptor blockade has been associated with antipsychotic activity (Willner *Int. Clinical Psychopharmacology* 1997, 12, 297-308). Furthermore, an elevation of the level of D₃ receptors in the limbic part of

schizophrenic brains has been reported (Gurevich et al. *Arch. Gen. Psychiatry* 1997, 54, 225-32). Therefore, D₃ receptor antagonists may offer the potential for an effective antipsychotic therapy, free of the extrapyramidal side effects of the classical antipsychotic drugs, which primarily exert their effect by blockade of D₂ receptors (Shafer et al. 5 *Psychopharmacology* 1998, 135, 1-16; Schwartz et al. *Brain Research Reviews* 2000, 31, 277-287).

Moreover, D₃ receptor blockade results in a slight stimulation in the prefrontal cortex (Merchant et al. *Cerebral Cortex* 1996, 6, 561-570), which could be beneficial against 10 negative symptoms and cognitive deficits associated with schizophrenia. In addition, dopamine D₃ antagonists can reverse D₂ antagonist-induced EPS (Millan et al. *Eur. J. Pharmacol.* 1997, 321, R7-R9) and do not cause changes in prolactin (Reavill et al. *J. Pharmacol. Exp. Ther.* 2000, 294, 1154-1165). Consequently, D₃ antagonistic properties of an antipsychotic drug could reduce the negative symptoms and cognitive deficits and result 15 in an improved side effect profile with respect to EPS and hormonal changes.

Dopamine D₃ agonists have also been considered relevant in the treatment of schizophrenia (Wustow et al. *Current Pharmaceutical Design* 1997, 3, 391-404).

20 Accordingly, agents acting on the 5-HT_{1A} receptor, both agonists and antagonists, are believed to be of potential use in the therapy of psychiatric and neurological disorders and thus being highly desired. Furthermore, antagonists at the same time having potent serotonin reuptake inhibition activity and/or D₄ and/or D₃ activity may be particularly useful for the treatment of various psychiatric and neurological diseases.

25

Structural similar compounds to the compounds of the present invention have been described earlier.

Thiophene derivatives are described in WO 9902516 as ligands for the 5-HT_{1A}- receptor.

WO 9726252 describes piperazinyl derivatives as insecticides.


30 WO 9514004 describes substituted alkylamino-indole derivatives as 5-HT_{1A} ,5-HT_{1B} and 5-HT_{1D}- derivatives.

It has now been found that compounds of a certain class of phenyl-piperazine derivatives bind to the 5-HT_{1A} receptor with high affinities. Furthermore, it has been found that many of these compounds have other highly beneficial properties as *i.e.* potent serotonin reuptake inhibition activity and/or affinity for the D₄ and/or the D₃ receptor.

5

Summary of the invention

Accordingly, the present invention relates to novel compounds of the general Formula I:



10

wherein Z represents NH, NR^{'''}, O or S; R^{'''} represents hydrogen, C₁₋₆-alkyl;

R⁷ and R⁸ independently represent hydrogen, halogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, CN, CF₃ or C₁₋₆-alkoxy; or R⁷ and R⁸ together form a 5- or 6-membered aryl or heteroaryl fused to

15 the benzene-ring;

Y represents N, C or CH;

the dotted line represents an optional bond;

R⁶ and R^{6'} represent H or C₁₋₆-alkyl;

20 X represents -O- or -S-


n is 2, 3, 4 or 5;

m is 2 or 3;

R¹, R², R³, R⁴ and R⁵ are independently selected from a group consisting of hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkenyl, C₁₋₆-alkynyl, C₃₋₈-cycloalkyl, aryl, hydroxy, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy, C₃₋₈-cycloalkoxy, C₁₋₆-alkylsulfanyl, acyl, NR⁹R¹⁰ wherein R⁹ and R¹⁰ independently represent hydrogen, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl or aryl; or R⁹ and R¹⁰ together with the nitrogen to which they are attached form a 1-

morpholinyl, 1-piperidinyl, 1-homopiperidinyl, 1-piperazinyl, 1-homopiperazinyl, 1-imidazolyl, 1-pyrrolyl, or pyrazolyl, all of which may be further substituted with C₁₋₆-alkyl; or two adjacent substituents of R¹ - R⁵ together form a ring fused to the phenyl ring selected from the group consisting of

5



wherein W is O or S, and R' and R'' are hydrogen or C₁₋₆-alkyl:

The compounds of the invention have affinity for the 5-HT_{1A} receptor. Accordingly, the invention provides:

10

A compound as above as a medicament.

A pharmaceutical composition comprising at least one compound of Formula I as defined above or a pharmaceutically acceptable acid addition salt thereof or prodrug thereof in a 15 therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.

The present invention provides the use of a compound of Formula I as defined above or an acid addition salt or prodrug thereof for the manufacture of a pharmaceutical preparation for 20 the treatment of the above mentioned disorders.

The invention provides a method for the treatment of diseases and disorders in humans caused by abnormalities in the serotonin system of the central nervous system comprising the administration of an effective amount of a compound of Formula I as above.

25

The compounds of the invention are considered useful for the treatment of affective disorders, such as depression, generalised anxiety disorder, panic disorder, obsessive compulsive disorders, social phobia, and eating disorders, psychosis and neurological disorders such as ischaemia and senile dementia.

30

Detailed Description of the Invention

A preferred embodiment of the invention is the compound of formula I as above wherein Z is NH and the resulting indole is connected in position 3;

5 Another preferred embodiment of the invention is the compound of formula I as above wherein R⁷ and R⁸ independently are selected from a hydrogen, halogen, C₁₋₆-alkyl or R⁷ and R⁸ together form a fused pyridyl-ring;

Another preferred embodiment of the invention is the compound of formula I as above wherein n is 2,3 or 4;

10 Another preferred embodiment of the invention is the compound of formula I as above wherein m is 2;

Another preferred embodiment of the invention is the compound of formula I as above wherein R⁶ and R^{6'} are both hydrogen;

Another preferred embodiment of the invention is the compound of formula I as above

15 wherein Y is N;

Another preferred embodiment of the invention is the compound of formula I as above wherein R¹, R², R³, R⁴ and R⁵ are independently selected from hydrogen, alkoxy, NR³R⁴ wherein R³ and R⁴ independently represent hydrogen, C₁₋₆-alkyl; or R³ and R⁴ together form a 1-morpholino; or two of adjacent of R¹, R², R³, R⁴ and R⁵ together form a fused ring

20 consisting of

-O-CH₂-O-,

-O-CH₂-CH₂-O-, or

-CH₂-CH₂-CH₂-;

Another preferred embodiment of the invention is the compound of formula I as above

25 wherein one or two of R¹, R², R³, R⁴, R⁵ are not hydrogen;

The most preferred embodiment of the invention is the compound according to formula I as above, the compound being:

30 1-{1-[3-(dimethylamino)phenoxy]phenyl}-4-[2-(1H-indol-3-yl)ethyl]piperazine;

1-[1-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[2-(1H-indol-3-yl)ethyl]piperazine;

1-{1-[3-(dimethylamino)phenoxy]phenyl}-4-[3-(1H-indol-3-yl)propyl]piperazine;

1-[1-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;

1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine,
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine,
1-[2-(1,4-Benzodioxan-6-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine
5 1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
1-[2-(1,4-Benzodioxan-6-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
10 1-(2-Phenoxyphenyl)-4-[4-(1H-indol-3-yl)butyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
1-[2-(3-Dimethylamino)phenoxy]phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
15 1-[2-(2-Methoxyphenoxy)phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine;
1-[2-(4-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Dimethylamino)phenoxy]phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine;
1-(2-Phenoxyphenyl)-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
20 1-(2-Phenoxyphenyl)-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
25 1-(2-Phenoxyphenyl)-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;
1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Dimethylamino)phenoxy]phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
30 1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(7-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
,

1-(2-Phenoxyphenyl)-4-[3-(7-chloro-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5,7-difluoro-1H-indol-3-yl)propyl]piperazine
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(7-bromo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-(Dimethylamino)phenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
5 1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h] quinolin-3-
yl)propyl]piperazine;
10 1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5,7-difluoro-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h] quinolin-3-yl)propyl]piperazine;
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h] quinolin-3-yl)propyl]piperazine;
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
15 1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;
1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
20 1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Ethoxyphenoxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-(Diethylamino)phenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
25 1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;
1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(7-fluoro-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5,7-dimethyl-1H-indol-3-yl)propyl]piperazine;
30 1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(7-bromo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3,4,5-Trimethoxyphenoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;

Some of the compounds of general Formula I may exist as optical isomers thereof and such optical isomers are also embraced by the invention.

The term C₁₋₆ alkyl refers to a branched or unbranched alkyl group having from one to six 5 carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl.

Similarly, C₂₋₆ alkenyl and C₂₋₆ alkynyl, respectively, designate such groups having from 10 two to six carbon atoms, inclusive and the groups are having at least one double bond or triple bond respectively;

Halogen means fluoro, chloro, bromo, or iodo.

The term C₃₋₈-cycloalkyl designates a monocyclic or bicyclic carbocycle having three to 15 eight C-atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Preferred embodiments are cyclopropyl, cyclopentyl, cyclohexyl.

The terms C₁₋₆ alkoxy, C₁₋₆ alkylsulfanyl, C₃₋₈-cycloalkoxy, designate such groups in which the alkyl group is C₁₋₆ alkyl as defined above.

20

Acyl means CHO and -CO-alkyl wherein the alkyl group is C₁₋₆ alkyl as defined above.

5- or 6-membered rings which are aryl or heteroaryl designates groups such as phenyl, pyrrolyl, pyridyl, pyrimidyl, furanyl, thienyl;

25

Exemplary of organic acid addition salts according to the invention are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanesulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of inorganic acid addition salts according to the invention are those with hydrochloric, hydrobromic, sulfuric,

sulfamic, phosphoric, and nitric acids. The acid addition salts of the invention are preferably pharmaceutically acceptable salts formed with non-toxic acids.

Furthermore, the compounds of this invention may exist in unsolvated as well as in solvated 5 forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

Some of the compounds of the present invention contain chiral centres and such compounds 10 exist in the form of isomers (e.g. enantiomers). The invention includes all such isomers and any mixtures thereof including racemic mixtures.

Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the 15 optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for example. The compounds of the present invention may also be 20 resolved by the formation of diastereomeric derivatives.

Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

25


Optically active compounds can also be prepared from optically active starting materials.

The compounds of the invention can be prepared by one of the following methods comprising:

30

a) reacting a secondary amine of the formula


11



III

wherein R¹-R⁶, X, Y and m are as defined above


5 with an alkylating agent of the general formula:



and R⁷, R⁸, Z and n are as defined above and G is a suitable leaving group such as halogen, mesylate or tosylate;

10

b) reacting a compound of the formula




IV

wherein R¹-R⁶, X, Y, n and m are as defined above and Q(OH)₂ is a diol such as substituted


15 ethylene glycol or propylene glycol or a polymer bound diol;

with a hydrazine of the formula



V

c) reducing an amide of formula




VI

5

wherein Z, R¹-R⁸, X, Y, n and m are as defined above.

d) reducing a compound of formula

10




VII

wherein R¹-R⁸, Y, X and m are as defined above


15 The alkylations according to method a are generally performed by boiling the reactants under reflux or by heating them at a fixed temperature in a suitable solvent such as acetone, acetonitrile, methyl isobutyl ketone, tetrahydrofuran, dioxane, ethanol, 2-propanol, ethyl acetate, N,N-dimethylformamide, dimethyl sulfoxide or 1-methyl-2-pyrrolidinone in the presence of a base such as triethylamine or potassium carbonate and optionally a catalytic
 20 amount of potassium iodide.

1)



Secondary amines of formula III are prepared by the reaction sequence outlined above. 2-Fluoro-nitrobenzene is reacted with a nucleophile of formula VIII in an aprotic solvent such as N,N-dimethylformamide using organic or inorganic basis at elevated temperature. After reduction of the intermediate nitro compound IX using standard conditions such as palladium catalysed hydrogenation or iron in acidic solvents, the aniline derivative X was transformed into the desired secondary amine of formula III. The piperazine formation was either performed by reaction with bis(2-chloroethyl)amine, hydrochloride at elevated temperature or in a multistep synthesis according to published procedures (Kruse et al., *Recl. Trav. Chim. Pays-Bas*, 1988, 107, 303-309).

2)



15 Alternatively, secondary amines of formula III are prepared using the mono substituted cyclic diamines of formula XII as key intermediate. The substituent R is an appropriate

protecting group such as a ethoxy-, methoxy- or 2-methyl-2-propyloxy-carbonyl group or a benzyl group, or a suitable solid support such as a Merrifield resin or a solid supported carbamate group such as the wang resin based carbamate linker (Zaragoza, *Tetrahedron Lett.*, 1995, 36, 8677-8678). The mono substituted cyclic diamines of formula XII are


5 prepared from commercially available starting materials or by methods obvious to the chemist skilled in the art. The mono substituted cyclic diamine of formula XII are reacted with η^6 -1,2-dichlorobezene- η^5 -cyclopentadienyliron(II) hexafluorophosphate at elevated temperature in an aprotic solvent such as dry tetrahydrofuran using an appropriate base such as potassium carbonate. η^6 -1,2-dichlorobezene- η^5 -cyclopentadienyliron(II)

10 hexafluorophosphate are prepared in analogy to literature procedures (Pearson and Gelormani, *J. Org. Chem.* 1994, 59, 4561-4570). The thus formed mono chloro derivative of formula XIII are subsequently reacted with a nucleophile of formula VIII in an aprotic solvent such as dry tetrahydrofuran either by the use of an appropriate base such as potassium carbonate or by deprotonation of the nucleophile of formula VIII using a base

15 such as sodium hydride prior to the reaction. Decomplexation, performed according to literature procedures (Pearson et al., *J. Org. Chem.* 1996, 61, 1297-1305), followed by deprotection by methods obvious to the chemist skilled in the art or cleavage from the solid support according to literature procedures (Zaragoza, *Tetrahedron Lett.*, 1995, 36, 8677-8678 and Conti et al., *Tetrahedron Lett.*, 1997, 38, 2915-2918) afforded the desired

20 secondary amines of formula III, corresponding to secondary amines of formula XV, R = H. Nucleophiles of formula VIII are commercially available, prepared by methods obvious to the chemist skilled in the art or according to literature procedures (Guillaumet and Hretani, *J. Heterocyclic Chem.*, 26, 193-196, 1989).

The alkylating agents of formula




25

are prepared according literature procedures (*J. Med. Chem.* 1983, 26, 1470-1477, Brodfuehrer et al., *J. Org. Chem.* 1997, 62, 9192-9202, Anelli, et al., *J. Org. Chem.* 1987, 52, 2559-2562, Brodfuehrer, et al., *J. Org. Chem.* 1997, 62, 9192-9202) or by methods obvious to the chemist skilled in the art.

30 The indole formation according to method b is performed by the reaction of acetals of formula IV with aryl hydrazines of formula V resulting in the corresponding hydrazones,


which subsequently are converted into indoles by means of the Fischer indole synthesis. The synthesis sequence is preferably performed as a one-pot procedure using a Lewis acid catalysts, preferably zinc chloride or boron trifluoride, or protic acids, preferably sulfuric acid or phosphoric acid, in a suitable solvent such as acetic acid or ethanol at an elevated 5 temperature.

Acetals of formula IV are prepared by the reaction sequence 2) outlined above using mono substituted cyclic diamines of formula XII wherein



10

as key intermediates. The key intermediates of formula XII are prepared by alkylation of cyclic diamines of formula XI with acetals of formula



XVI

15 using the conditions described above for methods a.

Polymer bound acetals of formula XVI are prepared by reaction of aldehydes of formula G- $(\text{CH}_2)_{n+1}\text{-CHO}$ with commercially available 2,2-dimethyl-1,3-dioxolan-4-yl-methoxymethyl polystyrene in a suitable solvent such as toluene, using p-toluenesulfonic acid as catalyst at elevated temperature. 4-Chlorobutanal, 5-chloropentanal, and 6-chlorohexanal were

20 prepared in analogy to the method described by Normant et al., *Tetrahedron* 1994, 50 (40), 11665.

The reductions according to Method c and d are generally performed by use of LiAlH_4 , AlH_3 or diborane in an inert solvent such as tetrahydrofuran, dioxane, or diethyl ether at 25 room temperature or at a slightly elevated temperature. The amides of formula VI are prepared from secondary amines of formula III and a substituted indol-3-ylalkylcarboxylic acids or carboxylic acid chlorides by methods obvious to the chemist skilled in the art. The amides of formula VII are prepared from 3-unsubstituted indoles and secondary amines of formula III according to literature multistep procedures (Nichols al., *Synthesis* 1999, 6, 935-30 938 and Speeter and Anthony, *J. Am. Chem. Soc.* 1954, 76, 6208-6210)

Examples

All reactions were carried out under a positive pressure of nitrogen. Melting points were determined on a Büchi SMP-20 apparatus and are uncorrected.

Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with

- 5 IonSpray source and Shimadzu LC-8A/SLC-10A LC system. The LC conditions (50 X 4.6 mm YMC ODS-A with 5 μ m particle size) were linear gradient elution with water/acetonitrile/trifluoroacetic acid (90:10:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 7 min at 2 ml/min. For compounds 3c, 3e, 3f, and 3l, the LC conditions (Waters Symmetry, 30x4.6 mmm, C18 3.5 μ m particle size) were linear gradient elution
- 10 with water/acetonitrile/trifluoroacetic acid (90:10:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 4 min at 2 ml/min. Purity was determined by integration of the UV trace (254 nm). The retention times R_t are expressed in minutes.

Preparative LC-MS-separation was performed on the same instrument. The LC conditions (50 X 20 mm YMC ODS-A with 5 μ m particle size) were linear gradient elution with

- 15 water/acetonitrile/trifluoroacetic acid (80:20:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 7 min at 22.7 mL/min. Fraction collection was performed by split-flow MS detection.

1 H NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or at 250.13 MHz on a Bruker AC 250 instrument. Deuterated chloroform (99.8%D) or

- 20 dimethyl sulfoxide (99.9%D) were used as solvents. TMS was used as internal reference standard. Chemical shift values are expressed in ppm-values. The following abbreviations are used for multiplicity of NMR signals: s=singlet, d=doublet, t=triplet, q=quartet, qui=qintet, h=heptet, dd=double doublet, dt=double triplet, dq=double quartet, tt=triplet of triplets, m=multiplet and b=broad singulet. NMR signals corresponding to acidic protons
- 25 are generally omitted.

Content of water in crystalline compounds was determined by Karl Fischer titration.

Standard workup procedures refer to extraction with the indicated organic solvent from proper aqueous solutions, drying of combined organic extracts (anhydrous MgSO₄ or Na₂SO₄), filtering and evaporation of the solvent *in vacuo*. For column chromatography,

- 30 silica gel of type Kieselgel 60, 230-400 mesh ASTM was used. For ion-exchange chromatography, the following material was used: SCX-columns (1 g) from Varian Mega Bond Elut®, Chrompack cat. No. 220776. Prior use the SCX-columns were pre-conditioned with 10 % solution of acetic acid in methanol (3 mL). For reversed phase chromatography,

the following material was used: C-18 columns (1 g) from Varian Mega Bond Elut®, Chrompack cat. No. 220508). Prior use the C-18-columns were pre-conditioned with methanol (3 mL) and water (3 mL). For decomplexation by irradiation, a ultaviolet light source (300 W) from Philipps was used.

5

Example 1

1-[2-[3-(dimethylamino)phenoxy]phenyl]-4-[2-(1H-indol-3-yl)ethyl]piperazine, oxalate (1a).

10 1-Chloro-2-nitrobenzene (15.0 g), 3-(dimethylamino)phenol (13.0 g) and potassium hydroxide (11.8 g) was dissolved in *N,N*-dimethylformamide (350 mL) and boiled under reflux for 18 hrs. The reaction was then cooled, and poured into water, and worked up by standard procedure using ethyl acetate. The crude product was purified by silicagel chromatography (heptane:ethyl acetate:triethylamine / 80:10:10). The pure intermediate
15 was dissolved in a mixture of ethanol (200 mL) and acetic acid (20 mL). After addition of Pd/C (5 %, 4.5 g), the reaction mixture was shaken under hydrogen atmosphere (3 bar) for 3 hrs. The reaction mixture was filtered and after neutralisation worked up by standard procedure using ethyl acetate affording pure aniline (11.2 g). The crude aniline, *bis*-(2-chloroethyl)amine hydrochloride (8.6 g) and chlorobenzene (200 mL) was boiled under
20 reflux for 48 hrs. The reaction mixture was cooled to room temperature, and the volatile solvents evaporated *in vacuo* to give the crude 1-[3-(dimethylamino)phenoxy]phenyl)piperazine (18.6 g). A solution of the crude piperazine, di-tert-butyl dicarbonate (32 g) and potassium carbonate (68 g) in tetrahydrofuran:water / 1:1, was heated at 50 °C for 18 hrs. The organic layer was separated and the water phase
25 extracted with ethyl acetate. The collected organic phases were worked up by standard procedure followed by purification by silicagel chromatography (heptane:ethyl acetate / 8:2) affording pure BOC-protected 1-[3-(dimethylamino)phenoxy]phenyl)piperazine (9.4 g). A solution of the BOC-derivative in a mixture of dry THF (30 mL) and trifluoroacetic acid (30 mL) was stirred at room temperature for 1 h. The volatile solvents were evaporated *in vacuo*
30 and ethyl acetate and 1 N aqueous sodium hydroxide were added. The organic phase was collected and worked up by standard procedure giving pure 1-[3-(dimethylamino)phenoxy]phenyl)piperazine (6.0g). A mixture of a part of the pure piperazine (1.37 g), 3-(2-bromoethyl)-1H-indole (1.0 g), potassium carbonate (2.2 g),

potassium iodide (cat.) and methyl isobutyl ketone was boiled under reflux for 24 hrs. The mixture was cooled to room temperature, filtered, and the volatile solvents evaporated *in vacuo* to give an oil which was purified by silicagel chromatography (heptane:ethyl acetate:triethylamine / 26:70:4) to give the title compound as an oil. The title compound was 5 crystallised as its oxalate from acetone (1.27 g). Mp 210-203 °C.

¹H NMR/250MHz (DMSO-d₆): 2.85 (s, 6H); 3.00-3.35 (m, 12H); 6.15 (d, 1H); 6.35 (s, 1H); 6.45 (d, 1H); 6.85 (d, 1H); 6.95-7.15 (m, 6H); 7.20 (s, 1H); 7.35 (d, 1H); 7.55 (d, 1H); 10.90 (s, 1H). MS: m/z: 441 (MH⁺), 144. Anal. Calcd. for C₂₈H₃₂N₄O: C, 67.89; H, 6.47; N, 10.56. Found C, 67.34; H, 6.59; N, 10.30.

10

The following compounds were prepared using the same general method:

1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[2-(1H-indol-3-yl)ethyl]piperazine, oxalate

(1b). Mp 221-228 °C. ¹H NMR (250MHz, DMSO-d₆): 3.00-3.35 (m, 12H); 6.00 (s, 2H); 15 6.40 (dd, 1H); 6.65 (d, 1H); 6.80-6.90 (m, 2H); 6.95-7.15 (m, 5H); 7.20 (d, 1H); 7.35 (d, 1H); 7.55 (d, 1H); 10.90 (s, 1H). MS: m/z: 443 (MH⁺), 311, 131. Anal. Calcd. For C₂₇H₂₇N₃O₃: C, 65.10; H, 5.54; N, 7.86. Found C, 64.86; H, 5.55; N, 7.60.

20 **Example 2**

1-[2-[3-(dimethylamino)phenoxy]phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine (2a).

To a suspension of lithium aluminum hydride (8.0 g) in tetrahydrofuran (500 mL) was a solution of 3-indolepropionic acid (20 g) in tetrahydrofuran (100 mL) added dropwise. The reaction mixture was stirred for 1 h at room temperature and subsequently cooled to 5 °C.

25 After sequential addition of water (16 mL), 15% aqueous sodium hydroxide (8.0 mL) and water (40 mL), the reaction mixture was stirred at room temperature over night and filtered. Evaporation of the volatile solvents gave pure 3-(1H-indol-3-yl)propanol (19.1 g) as an oil. 3-(1H-Indol-3-yl)propanol (18.6 g) and carbon tetrabromide (42.1 g) was dissolved in acetonitrile (1 L) and cooled to 0 °C and triphenylphosphine (30.7 g) was added in small 30 portions. The reaction was stirred for further 3 h at room temperature, the volatile solvents evaporated *in vacuo* and the remaining oil purified by silicagel chromatography (heptane:ethyl acetate / 2:1) to give 3-(3-bromopropyl)-1H-indole (25.6 g).

This intermediate was coupled to the piperazine moieties using the method described in Example 1 to give the title compound isolated as an amorphous solid. ¹H NMR (250MHz, DMSO-d₆): 1.80 (q, 2H); 2.25-2.40 (m, 6H); 2.65 (t, 2H); 2.85 (s, 6H); 3.05 (m, 4H); 6.10 (dd, 1H); 6.30 (t, 1H); 6.45 (dd, 1H); 6.80-7.10 (m, 8H); 7.30 (d, 1H); 7.50 (d, 1H); 10.70 5 (b, 1H). MS: m/z: 455 (MH⁺), 295, 239, 201, 130.

The following compounds were prepared analogously:

1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine, oxalate 10 (2b). Mp 156-162 °C. ¹H NMR (250MHz, DMSO-d₆): 1.80 (q, 2H); 2.25-2.40 (m, 6H); 2.70 (t, 2H); 3.05 (m, 4H); 6.00 (s, 2H); 6.35 (dd, 1H); 6.55 (d, 1H); 6.85 (d, 2H); 6.90-7.15 (m, 6H); 7.30 (d, 1H); 7.50 (d, 1H); 10.75 (s, 1H). MS: m/z: 456 (MH⁺), 297, 201, 130. Anal. Calcd. For C₂₈H₂₉N₃O₃: C, 73.81; H, 6.43; N, 9.23. Found C, 73.28; H, 6.45; N, 9.00.

15 1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine, dihydrochloride (2c). Mp: 165 °C (decomposition). ¹H NMR (250MHz, DMSO-d₆): 2.08 (m, 2H); 2.73 (t, 2H); 3.02 (m, 2H); 3.15 (m, 4H); 3.55 (t, 4H); 6.00 (s, 2H); 6.40 (d, 1H); 6.65 (s, 1H); 6.80 (d, 1H), 6.85 (d, 1H); 7.00 (m, 2H); 7.05 (m, 2H); 7.25 (d, 1H); 7.38 (s, 1H); 7.55 (dd, 1H); 10.45 (s, 1H), 11.00 (s, 1H). MS (m/z): 490 (MH⁺). Anal. Calcd. for 20 C₂₈H₃₀Cl₃N₃O₃: C, 59.73; H, 5.38; N, 7.47. Found C, 59.13; H, 5.36; N, 7.26.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine, dihydrochloride (2d). Mp: 183-189 °C. ¹H NMR (500MHz, DMSO-d₆): 2.12 (m, 2H); 2.73 (t, 2H); 3.05-3.25 (m, 6H); 3.55 (d, 2H); 3.65 (d, 2H); 3.75 (s, 3H); 6.53 (m, 1H); 6.88-7.20 25 (m, 9H); 7.27-7.40 (m, 3H); 11.05 (s, 2H). MS (m/z): 460 (MH⁺). Anal. Calcd. for C₂₈H₃₂Cl₂FN₃O₂: C, 63.16; H, 6.06; N, 7.89. Found C, 63.04; H, 6.07; N, 7.88.

1-[2-(1,4-Benzodioxan-6-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine (2e). ¹H NMR (250MHz, CDCl₃): 1.90 (qui, 2H); 2.40-2.60 (m, 6H); 2.79 (t, 2H); 3.15 (t, 4H); 4.22 30 (s, 4H); 6.45 (m, 2H); 6.77 (d, 1H); 6.85-7.22 (m, 7H); 7.35 (d, 1H); 7.60 (d, 1H); 7.92 (s, 1H). MS (m/z): 470 (MH⁺).

1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine (2f). ^1H NMR (250MHz, CDCl_3): 1.90 (qui, 2H); 2.38-2.53 (m, 6H); 2.73 (t, 2H); 3.16 (t, 4H); 4.26 (s, 4H); 6.38 (dd, 1H); 6.60-6.75 (m, 2H); 6.83-7.10 (m, 6H); 7.23-7.30 (m, 3H); 7.92 (s, 1H). LC/MS (m/z): 488 (MH $^+$), Rt = 2.53, purity 99.8%

5

1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine (2g). ^1H NMR (250MHz, CDCl_3): 1.90 (qui, 2H); 2.35-2.50 (m, 6H); 2.75 (t, 2H); 3.18 (t, 4H); 4.28 (s, 4H); 6.40 (dd, 1H); 6.60-6.75 (m, 3H); 6.80-7.08 (m, 6H); 7.32 (d, 1H); 7.50 (d, 1H); 7.95 (s, 1H). LC/MS (m/z): 504 (MH $^+$), Rt = 2.60, purity 99.6%

10

1-[2-(1,4-Benzodioxan-6-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine (2h). ^1H NMR (250MHz, CDCl_3): 1.90 (qui, 2H); 2.35-2.55 (m, 6H); 2.75 (t, 2H); 3.15 (t, 4H); 4.23 (s, 4H); 6.45 (m, 2H); 6.78-6.15 (m, 7H); 7.32 (d, 1H), 7.50 (d, 1H); 7.92 (s, 1H). LC/MS (m/z): 504 (MH $^+$), Rt = 2.62, purity 99.7%

15

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine (2i). 6-Chloro-3-(3-{4-[2-(2-methoxy-phenoxy)-phenyl]-piperazin-1-yl}-propyl)-1H-indole ^1H NMR (250MHz, CDCl_3): 1.90 (qui, 2H); 2.35-2.50 (m, 6H); 2.73 (t, 2H); 3.19 (t, 4H); 3.83 (s, 3H); 6.70-7.08 (m, 10H); 7.32 (d, 1H), 7.49 (d, 1H); 7.94 (s, 1H). LC/MS (m/z): 476 (MH $^+$), Rt = 2.59, purity 99.8%

20

1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine (2j). ^1H NMR (250MHz, CDCl_3): 1.89 (qui, 2H); 2.33-2.60 (m, 6H); 2.73 (t, 2H); 3.13 (t, 4H); 3.75 (s, 3H); 6.49 (m, 2H); 6.58 (dd, 1H); 6.95-7.20 (m, 7H); 7.32 (d, 1H), 7.49 (d, 1H); 7.92 (s, 1H). LC/MS (m/z): 476 (MH $^+$), Rt = 2.64, purity 99.7%

Example 3

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine (3a)

30

4-[(4-Nitrophenoxy)carbonyloxymethyl]phenoxyethyl polystyrene (267.0 g, 235 mmol) was suspended in dry N,N-dimethylformamide (2 L). N-Methylmorpholine (238.0 g, 2.35 mol) and piperazine (102.0 g, 1.17 mol) were added and the mixture was stirred at room temperature for 16 hrs. The resin was filtered off and washed with N,N-dimethylformamide

(2 X 1L), tetrahydrofuran (2 X 1 L), water (1 X 500 mL), methanol (2 X 1 L), tetrahydrofuran (2 X 1 L), methanol (1 X 1 L). Finally, the resin was washed with dichloromethane (3 X 500 mL) and dried *in vacuo* (25 °C, 36 hrs) to yield an almost colourless resin (240.0 g).

5

A part of the resin thus obtained (115.1 g, 92 mmol) was suspended in dry tetrahydrofuran (1.6 L) and η^6 -1,2-dichlorobenzene- η^5 -cyclopentadienyliron(II) hexafluorophosphate (76.0 g, 184 mmol) was added followed by potassium carbonate (50.9 g, 368 mmol). The reaction mixture was stirred at 60 °C for 16 hrs. After cooling to room temperature, the resin was 10 filtered off and washed with tetrahydrofuran (2 X 500 mL), water (2 X 250 mL), tetrahydrofuran (2 X 500 mL), water (2 X 250 mL), methanol (2 X 250 mL), dichloromethane (2 X 500 mL), methanol (2 X 250 mL). Finally, the resin was washed with dichloromethane (3 X 500 mL) and dried *in vacuo* (25 °C, 36 hrs) to yield a dark orange resin (142 g).

15

To a solution of 2-hydroxyanisole (2.2 g, 17.7 mmol) in tetrahydrofuran (50 mL) was carefully added neat sodium hydride (15.5 mmol) at room temperature (Caution: Generation of hydrogen). The mixture was stirred additional 30 min after the generation of hydrogen ceased. Subsequently, a part of the above obtained resin (2.8 g, 1.72 mmol) was added and 20 the mixture was stirred at 40 °C for 12 hrs. After cooling to room temperature, the resin was filtered off and washed with tetrahydrofuran (2 X 50 mL), tetrahydrofuran/water (1:1) (2 X 50 mL), N,N-dimethylformamide (2 X 50 mL), water (2 X 50 mL), methanol (3 X 50 mL), tetrahydrofuran (3 X 50 mL), and subsequently with methanol and tetrahydrofuran (each 50 mL, 5 cycles). Finally, the resin was washed with dichloromethane (3 X 50 mL) and dried *in* 25 *vacuo* (25 °C, 12 hrs).

The thus obtained resin (3.0 g, 1.84 mmol) and a 0.5 M solution of 1,10-phenanthroline in a 3:1 mixture of pyridine/water (20 mL) was placed in a light-transparent reactor tube. For decomplexation, the suspension was vortexed and irradiated with visible light for 12 hrs. A 30 very characteristic feature of the decomplexation step is the appearance of the intensive red colour of the liquid phase during irradiation. The resin was filtered off and washed with methanol (2 X 25 mL), water (2 X 25 mL) and tetrahydrofuran (3 X 25 mL) until the washing solutions kept colourless (5 cycles) and the irradiation procedure was repeated until

decomplexation was complete (5 cycles). After complete decomplexation, the resin was washed with dichloromethane (3 X 25 mL) and dried *in vacuo* (25 °C, 12 h).

The resin (approx. 2.5 g, 1.84 mmol) was suspended in a 1:1-mixture of trifluoroacetic acid 5 and dichloromethane (25 mL) and stirred at room temperature for 2 hrs. The resin was filtered off and washed with methanol (1 X 5 mL) and dichloromethane (1 X 5 mL). The liquid phases were combined and the volatile solvents were evaporated to yield a dark brown oil (1.5 g)

10 The oil was dissolved in acetonitril (10 mL). To the thus obtained solution, potassium carbonate (46 mg, 0.33 mmol) and 3-(3-bromopropyl)-1H-indole (33 mg, 0.14 mmol) were added and the mixture was heated at 70 °C for 12 hrs. Isocyanomethyl polystyrene (250 mg, 0.29 mmol) was added and the mixture was slowly cooled to room temperature. The resin was filtered off and washed with methanol (1 X 2 mL) and dichloromethane (1 X 15 2 mL). The combined liquid phases were evaporated from volatile solvents to yield a dark brown oil. The crude product was purified by preparative reversed phase HPLC chromatography. The resulting solution was subsequently loaded on a pre-conditioned ion exchange column. The column was washed with methanol (4 mL) and acetonitrile (4 mL), followed by elution of the product with 4 N solution of ammonia in methanol (4.5 mL).
20 Evaporation of the volatile solvents afforded the title compound 3a as yellow oil (66 mg). LC/MS (m/z) 442 (MH⁺), Rt = 4.15, purity: 93 %.

The following compounds were prepared analogously:

1-(2-Phenoxyphenyl)-4-[4-(1H-indol-3-yl)butyl]piperazine (3b): LC/MS (m/z) 426 (MH⁺),
25 RT = 4.36, purity: 79 %.

1-[2-(1,3-Benzodioxolan-5-yl)phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine (3c):
LC/MS (m/z) 470 (MH⁺), RT = 2.62, purity: 89 %.

30 1-[2-(2-Methoxyphenoxy)phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine (3d):
LC/MS (m/z) 462 (MH⁺), RT = 4.35, purity: 76 %.

1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine (3e): LC/MS (m/z) 476 (MH⁺), RT = 2.64, purity: 89 %.

1-[2-[3-(Dimethylamino)phenoxy]phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine (3f): LC/MS (m/z) 475 (MH⁺), RT = 2.32, purity: 91 %.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine (3g): LC/MS (m/z) 456 (MH⁺), RT = 4.31, purity: 90 %.

10 1-[2-(4-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine (3h): LC/MS (m/z) 442 (MH⁺), RT = 4.18, purity: 90 %.

15 1-[2-[3-(Dimethylamino)phenoxy]phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine (3i): LC/MS (m/z) 469 (MH⁺), RT = 2.27, purity: 88 %.

1-(2-Phenoxyphenyl)-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine (3j): LC/MS (m/z) 432 (MH⁺), RT = 4.40, purity: 70 %.

Example 4

20

2-(4-Chlorobutyl)-1,3-dioxolan-4-ylmethoxymethyl polystyrene (4a).

A 2 L round bottom flask was charged with 2,2-dimethyl-1,3-dioxolan-4-ylmethoxymethyl polystyrene (90 g, 72 mmol, commercially available as (\pm)-1-(2,3-isopropylidene) glycerol 25 polystyrene from Calbiochem-Novabiochem, cat. no. 01-64-0291). Toluene (900 mL) followed by p-toluenesulfonic acid mono hydrate (5.0 g, 26 mmol), sodium sulfate (25 g), and 5-chloropentanal (25.5 g, 211 mmol) were added and the mixture was boiled under reflux for 12 hrs. The reflux condenser was replaced by a Dean-Stark apparatus and the mixture was boiled under reflux for an additional 3 hrs. After cooling of the reaction 30 mixture to 60 °C, the resin was filtered off and washed with toluene (200 mL), tetrahydrofuran/pyridine (1:1, 200 mL), tetrahydrofuran/water/pyridine (10:10:1, 200 mL), methanol (200 mL), water (200 mL), tetrahydrofuran (200 mL), dichloromethane (200 mL), methanol (3 X 200 mL), and dichloromethane (3 X 200 mL). The resin was dried *in vacuo* (55 °C, 12 hrs) to yield the title compound 4a (97 g).

The following compounds were prepared analogously:

2-(3-Chloropropyl)-1,3-dioxolan-4-ylmethoxymethyl polystyrene (4b)

2-(5-Chloropentyl)-1,3-dioxolan-4-ylmethoxymethyl polystyrene (4c)

5

Example 5

1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine (5a).

10

2-(3-Chlorobutyl)-1,3-dioxolan-4-ylmethoxymethyl polystyrene (70 g, 90.3 mmol) was suspended in dry N,N-dimethylformamide (700 mL). Sodium iodide (68 g, 452 mmol) was added followed by diisopropylethylamine (232 mL, 1.36 mol) and piperazine (117 g, 1.36 mol). The reaction mixture was heated at 80 °C under stirring for 12 hrs. After cooling to room temperature, the resin was filtered off and washed with N,N-dimethylformamide (3 X 500 mL), methanol (3 X 500 mL), tetrahydrofuran (3 X 500 mL), and subsequently with methanol and tetrahydrofuran (each 250 mL, 5 cycles). Finally, the resin was washed with dichloromethane (3 X 500 mL) and dried *in vacuo* (25 °C, 36 hrs) to yield an almost colourless resin (76 g).

20

A part of the obtained resin (50 g, 60.6 mmol) was then suspended in dry tetrahydrofuran (600 mL). η^6 -1,2-Dichlorobenzene- η^5 -cyclopentadienyliron(II) hexafluorophosphate (48 g, 116.2 mmol) was added followed by potassium carbonate (32 g, 233 mmol). The reaction mixture was stirred at 60 °C for 12 hrs. After cooling to room temperature, the resin was filtered off and washed with tetrahydrofuran (2 X 500 mL), water (2 X 250 mL), tetrahydrofuran (2 X 500 mL), methanol (2 X 250 mL), dichloromethane (2 X 500 mL), methanol (2 X 250 mL). Finally, the resin was washed with dichloromethane (3 X 500 mL) and dried *in vacuo* (25 °C, 36 hrs) to yield a dark orange resin (70 g).

30 To a solution of 5-hydroxy-1,4-benzodioxane (2.8 g, 18.4 mmol) in tetrahydrofuran (50 mL) was carefully added neat sodium hydride (15.5 mmol) at room temperature (Caution: Generation of hydrogen). The mixture was stirred for an additional 30 min after the generation of hydrogen ceased. Subsequently, a part of the above obtained resin (2.8 g, 2.3

mmol) was added and the mixture was stirred at 40 °C for 12 hrs. After cooling to room temperature, the resin was filtered off and washed with tetrahydrofuran (2 X 50 mL), tetrahydrofuran/water (1:1) (2 X 50 mL), N,N-dimethylformamide (2 X 50 mL), water (2 X 50 mL), methanol (3 X 50 mL), tetrahydrofuran (3 X 50 mL), and subsequently with 5 methanol and tetrahydrofuran (each 50 mL, 5 cycles). Finally, the resin was washed with dichloromethane (3 X 50 mL) and dried *in vacuo* (25 °C, 12 hrs).

A part of the obtained resin (200 mg, 0.15 mmol) and a 0.5 M solution of 1,10-phenanthroline in a (3:1)-mixture of pyridine/water (10 mL) was placed in a light-10 transparent reactor tube. The suspension was vortexed and irradiated for 12 hrs. A very characteristic feature of the decomplexation step is the appearance of the intensive red colour of the liquid phase during irradiation. The resin was filtered off and washed with methanol (2 X 10 mL), water (2 X 10 mL) and tetrahydrofuran (3 X 10 mL) until the washing solutions kept colourless (ca. 5 cycles) and the irradiation procedure was repeated 15 until decomplexation was complete (ca. 4 cycles). After complete decomplexation, the resin was washed with dichloromethane (3 X 10 mL) and dried *in vacuo* (25 °C, 12 hrs).

The obtained resin (160 mg, 0.15 mmol) and 4-fluorophenylhydrazine hydrochloride (35 20 mg, 0.21 mmol) were mixed in a reactor tube. A 0.5 M solution of anhydrous zinc chloride in acetic acid (1.5 mL) was added and the reaction tube was sealed. The reaction mixture was stirred for 12 hrs at 70 °C. After cooling to room temperature, the reaction mixture was filtered and the residual resin washed with dimethyl sulfoxide (1.5 mL). Saturated aqueous sodium carbonate solution (1.5 mL) was added carefully to the combined filtrates(Caution: 25 Generation of carbondioxide). The solution was loaded on a pre-conditioned reversed phase C-18 column. The column was washed with water (4 mL) and the product was eluted with methanol (4.5 mL). After evaporation of the volatile solvents, the crude product was purified by preparative reversed phase HPLC chromatography. The resulting solution was subsequently loaded on a pre-conditioned ion exchange column. The column was washed 30 with methanol (4 mL) and acetonitrile (4 mL), followed by elution of the product with 4 N solution of ammonia in methanol (4.5 mL). Evaporation of the volatile solvents afforded the title compound 5a as yellow oil (2 mg). LC/MS (m/z) 488 (MH⁺), Rt = 4.22, purity: 84 %.

The following compounds were prepared analogously:

5 *1-(2-Phenoxyphenyl)-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine (5b)*: LC/MS (m/z) 426 (MH⁺), RT = 4.44, purity: 88 %.

5 *1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine (5c)*: LC/MS (m/z) 476 (MH⁺), RT = 4.46, purity: 95 %.

10 *1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine (5d)*: LC/MS (m/z) 522 (MH⁺), RT = 4.52, purity: 91 %.

10 *1-(2-Phenoxyphenyl)-4-[3-(1H-indol-3-yl)propyl]piperazine (5e)*: LC/MS (m/z) 412 (MH⁺), RT = 4.25, purity: 98 %.

15 *1-(2-Phenoxyphenyl)-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine (5f)*: LC/MS (m/z) 430 (MH⁺), RT = 4.32, purity: 96 %.

15 *1-(2-Phenoxyphenyl)-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine (5g)*: LC/MS (m/z) 492 (MH⁺), RT = 4.60, purity: 84 %.

20 *1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine (5h)*: LC/MS (m/z) 552 (MH⁺), RT = 4.49, purity: 86 %.

25 *1-[2-[3-(Dimethylamino)phenoxy]phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine (5i)*: LC/MS (m/z) 469 (MH⁺), RT = 3.73, purity: 86 %.

25 *1-(2-Phenoxyphenyl)-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine (5j)*: LC/MS (m/z) 446 (MH⁺), RT = 4.52, purity: 88 %.

30 *1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine (5k)*: LC/MS (m/z) 470 (MH⁺), RT = 4.38, purity: 70 %.

30 *1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine (5l)*: LC/MS (m/z) 460 (MH⁺), RT = 4.24, purity: 87 %.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(7-chloro-1H-indol-3-yl)propyl]piperazine (5m):
LC/MS (m/z) 476 (MH⁺), RT = 4.42, purity: 96 %.

5 *1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine (5n):* LC/MS (m/z) 474 (MH⁺), RT = 4.25, purity: 99 %.

1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine (5o): LC/MS (m/z) 582 (MH⁺), RT = 4.58, purity: 85 %.

10 *1-(2-Phenoxyphenyl)-4-[3-(7-chloro-1H-indol-3-yl)propyl]piperazine (5p):* LC/MS (m/z) 430 (MH⁺), RT = 4.38, purity: 87 %.

15 *1-(2-Phenoxyphenyl)-4-[3-(5,7-difluoro-1H-indol-3-yl)propyl]piperazine (5q):* LC/MS (m/z) 448 (MH⁺), RT = 4.44, purity: 84 %.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(7-bromo-1H-indol-3-yl)propyl]piperazine (5r):
LC/MS (m/z) 520 (MH⁺), RT = 4.50, purity: 77 %.

20 *1-[2-[3-(Dimethylamino)phenoxy]phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine (5s):* LC/MS (m/z) 473 (MH⁺), RT = 3.63, purity: 96 %.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine (5t):
LC/MS (m/z) 568 (MH⁺), RT = 4.63, purity: 82 %.

25 *1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine (5u):* LC/MS (m/z) 490 (MH⁺), RT = 4.45, purity: 90 %.

30 *1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine (5v):*
LC/MS (m/z) 506 (MH⁺), RT = 4.46, purity: 83 %.

1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h]-quinolin-3-yl)propyl]piperazine (5w): LC/MS (m/z) 507 (MH⁺), RT = 3.30, purity: 97 %.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5,7-difluoro-1H-indol-3-yl)propyl]piperazine (5x):
LC/MS (m/z) 478 (MH⁺), RT = 4.36, purity: 75 %.

5 *1-(2-Phenoxyphenyl)-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine (5y):* LC/MS (m/z) 5.38
(MH⁺), RT = 4.69, purity: 92 %.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h]quinolin-3-yl)propyl]piperazine
(5z): LC/MS (m/z) 493.2 (MH⁺), RT = 3.29, purity: 96 %.

10 *1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h]quinolin-3-yl)propyl]piperazine*
(5aa): LC/MS (m/z) 493 (MH⁺), RT = 3.38, purity: 96 %.

15 *1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine*
(5ab): LC/MS (m/z) 484 (MH⁺), RT = 4.35, purity: 84 %.

1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine
(5ac): LC/MS (m/z) 486 (MH⁺), RT = 4.38, purity: 80 %.

20 *1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine (5ad):* LC/MS
(m/z) 442 (MH⁺), RT = 4.25, purity: 85 %.

1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine (5ae):
LC/MS (m/z) 471 (MH⁺), RT = 4.13, purity: 83 %.

25 *1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine*
(5af): LC/MS (m/z) 536 (MH⁺), RT = 4.49, purity: 88 %.

30 *1-[2-[3-(Morpholin-4-yl)phenoxy]phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine*
(5ag): LC/MS (m/z) 515 (MH⁺), RT = 4.17, purity: 94 %.

1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine (5ah):
LC/MS (m/z) 476 (MH⁺), RT = 4.53, purity: 92 %.

1-[2-(3-Ethoxypheoxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine (**5ai**):
LC/MS (m/z) 470 (MH⁺), RT = 4.68, purity: 85 %.

5 1-[2-(2,6-Dimethoxypheoxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine (**5aj**):
LC/MS (m/z) 598 (MH⁺), RT = 4.61, purity: 70 %.

1-[2-[3-(Diethylamino)phenoxy]phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine
(**5ak**): LC/MS (m/z) 501 (MH⁺), RT = 3.18, purity: 87 %.

10

1-[2-(2,6-Dimethoxypheoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine (**5al**):
LC/MS (m/z) 490 (MH⁺), RT = 4.26, purity: 88 %.

15

1-[2-[3-(Morpholin-4-yl)phenoxy]phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine
(**5am**): LC/MS (m/z) 475 (MH⁺), RT = 4.42, purity: 78 %.

1-[2-[3-(Morpholin-4-yl)phenoxy]phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine
(**5an**): LC/MS (m/z) 531 (MH⁺), RT = 4.34, purity: 81 %.

20

1-[2-[3-(Morpholin-4-yl)phenoxy]phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine
(**5ao**): LC/MS (m/z) 623 (MH⁺), RT = 4.56, purity: 71 %.

1-[2-(3-Methoxypheoxy)phenyl]-4-[3-(7-fluoro-1H-indol-3-yl)propyl]piperazine (**5aq**):
LC/MS (m/z) 460 (MH⁺), RT = 4.38, purity: 70 %.

25

1-(2-Phenoxyphenyl)-4-[3-(5,7-dimethyl-1H-indol-3-yl)propyl]piperazine(**5ar**): LC/MS
(m/z) 440 (MH⁺), RT = 4.64, purity: 78 %.

30

1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(7-bromo-1H-indol-3-yl)propyl]piperazine
(**5as**): LC/MS (m/z) 534 (MH⁺), RT = 4.46, purity: 75 %.

1-[2-(3,4,5-Trimethoxypheoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine
(**5at**): LC/MS (m/z) 580 (MH⁺), RT = 4.34, purity: 81 %.

Pharmacological Testing

5 The compounds of the invention were tested in well-recognised and reliable methods. The tests were as follows:

Inhibition of the binding of ^3H -YM-09151-2 to human dopamine D₄ receptors

10 By this method, the inhibition by drugs of the binding of [^3H]YM-09151-2 (0.06 nM) to membranes of human cloned dopamine D_{4,2} receptors expressed in CHO-cells is determined *in vitro*. Method modified from NEN Life Science Products, Inc., technical data certificate PC2533-10/96. The results are given in the following Table 1 as IC₅₀-values.

15

Inhibition of the binding of [^3H]-Spiperone to human D₃ receptors

By this method, the inhibition by drugs of the binding [^3H]Spiperone (0.3 nM) to membranes of human cloned dopamine D₃ receptors expressed in CHO-cells is determined

20 *in vitro*. Method modified from R.G. MacKenzie *et al.*, *Eur. J. Pharm.-Mol. Pharm. Sec.*, 1994, 266, 79-85. The results are given in the following Table 1 as IC₅₀-values.

25 The affinity of the compounds of the invention to 5-HT_{1A} receptors was determined by measuring the inhibition of binding of a radioactive ligand at 5-HT_{1A} receptors as described in the following test:

Inhibition of ^3H -5-CT Binding to Human 5-HT_{1A} Receptors.

30

By this method, the inhibition by drugs of the binding of the 5-HT_{1A} agonist ^3H -5-carboxamido tryptamine (^3H -5-CT) to cloned human 5-HT_{1A} receptors stably expressed in transfected HeLa cells (HA7) (Fargin, A. *et al.*, *J. Biol. Chem.*, 1989, 264, 14848) is determined *in vitro*. The assay was performed as a modification of the method

35 described by Harrington, M.A. *et al.*, *J. Pharmacol. Exp. Ther.*, 1994, 268, 1098. Human 5-

HT_{1A} receptors (40 µg of cell homogenate) were incubated for 15 minutes at 37 °C in 50 mM Tris buffer at pH 7.7 in the presence of ³H-5-CT. Non-specific binding was determined by including 10 µM of metergoline. The reaction was terminated by rapid filtration through Unifilter GF/B filters on a Tomtec Cell Harvester. Filters were counted in a Packard Top

5 Counter. The results obtained are presented in table 1 below.

Inhibition of ³H-5-HT Uptake Into Rat Brain Synaptosomes

10 Using this method, the ability of drugs to inhibit the accumulation of ³H-5-HT into whole rat brain synaptosomes is determined *in vitro*. The assay was performed as described by Hyttel, J., *Psychopharmacology* 1978, 60, 13. The results obtained are presented in table 1:


Table 1:

Compound No.	Inhibition of ³ H-5-CT Binding IC ₅₀ (nM)	Inhibition of ³ H-5-HT Uptake IC ₅₀ (nM)
1b	7.8	130
2b	16	2.8
3c	16	27% inhibition at 100nM
3e	24	40% inhibition at 100 nM
5a	19	14
5e	10	13
5f	10	4.8
5h	10	55% inhibition at 100nM
5i	10	46 % inhibition at 100nM
5l	13	4.7
5x	18	33
5ae	26	42% inhibition at 100nM
5ag	26	23
5ai	28	34% inhibition at 100nM

Accordingly, as the compounds of the invention show affinities in the described tests, they are considered useful in the treatment of affective disorders, such as depression, generalised anxiety disorder, panic disorder, obsessive compulsive disorders, social phobia, and eating disorders, psychosis and neurological disorders such as ischaemia and senile dementia.

Claims:

1. A compound represented by the general formula I



5

wherein Z represents NH, NR^{'''}, O or S; R^{'''} represents hydrogen, C₁₋₆-alkyl;

R⁷ and R⁸ independently represent hydrogen, halogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, CN, CF₃
 10 or C₁₋₆-alkoxy; or R⁷ and R⁸ together form a 5- or 6-membered aryl or heteroaryl fused to
 the benzene-ring.

Y represents N, C or CH;


the dotted line represents an optional bond;

15 R⁶ and R^{6'} represent H or C₁₋₆-alkyl;

X represents -O- or -S- n is 2, 3, 4 or 5;

m is 2 or 3;

20 R¹, R², R³, R⁴ and R⁵ are independently selected from a group consisting of hydrogen,
 halogen, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, aryl, hydroxy, hydroxy-C₁₋₆-
 alkyl, C₁₋₆-alkoxy, C₃₋₈-cycloalkoxy, C₁₋₆-alkylsulfanyl, acyl, NR⁹R¹⁰ wherein R⁹ and R¹⁰
 independently represent hydrogen, C₁₋₆-alkyl, C₁₋₆-alkenyl, C₁₋₆-alkynyl, C₃₋₈-cycloalkyl or
 aryl; or R⁹ and R¹⁰ together with the nitrogen to which they are attached form a 1-
 morpholiny, 1-piperidiny, 1-homopiperidiny, 1-piperaziny, 1-homopiperaziny, 1-
 imidazolyl, 1-pyrrolyl, or pyrazolyl, all of which may be further substituted with C₁₋₆-alkyl;
 25 or two adjacent substituents of R¹- R⁵ together form a ring fused to the phenyl ring selected
 from the group consisting of



wherein W is O or S, and R' and R'' are hydrogen or C₁₋₆-alkyl:

2. The compound according to claim 1 wherein Z is NH and the aryl is connected in position 3;
3. The compound according to any of the preceding claims wherein R⁷ and R⁸ independently are selected from a hydrogen, halogen, C₁₋₆-alkyl or R⁷ and R⁸ together form a fused pyridyl-ring;
4. The compound according to any of the preceding claims wherein n is 2,3 or 4;
5. The compound according to any of the preceding claims wherein m is 2;
- 15 6. The compound according to any of the preceding claims wherein R⁶ and R^{6'} are both hydrogen;
7. The compound according to any of the preceding claims Y is N;
- 20 8. The compound according to any of the preceding claims wherein R¹, R², R³, R⁴ and R⁵ independently are selected from hydrogen, alkoxy, NR³R⁴ wherein R³ and R⁴ independently represent hydrogen, C₁₋₆-alkyl; or R³ and R⁴ together form a 1-morpholino; or two of adjacent of R¹, R², R³, R⁴ and R⁵ together form a fused ring consisting of -O-CH₂-O-, -O-CH₂-CH₂-O-, or -CH₂-CH₂-CH₂-;
- 25 9. The compound according to any of the preceding claims wherein one or two of R¹, R², R³, R⁴ and R⁵ are not hydrogen;
10. The compound according to any of the preceding claims, said compound being

1-[1-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[2-(1H-indol-3-yl)ethyl]piperazine;
1-[1-[3-(dimethylamino)phenoxy]phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-[1-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine,
5 1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine,
1-[2-(1,4-Benzodioxan-6-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
1-[2-(1,4-Benzodioxan-6-yloxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
10 1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(6-chloro-1H-indol-3-yl)propyl]piperazine
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[4-(1H-indol-3-yl)butyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine;
15 1-[2-(2-Methoxyphenoxy)phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
1-[2-(3-(Dimethylamino)phenoxy)phenyl]-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine;
1-[2-(4-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
20 1-[2-(3-(Dimethylamino)phenoxy)phenyl]-4-[4-(1H-indol-3-yl)butyl]piperazine;
1-(2-Phenoxyphenyl)-4-[2-(6-chloro-1H-indol-3-yl)ethyl]piperazine;
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
25 1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine.

1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(7-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(7-chloro-1H-indol-3-yl)propyl]piperazine;

5 1-(2-Phenoxyphenyl)-4-[3-(5,7-difluoro-1H-indol-3-yl)propyl]piperazine
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(7-bromo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-(Dimethylamino)phenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;

10 1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h] quinolin-3-yl)propyl]piperazine;
1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(5,7-difluoro-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;

15 1-[2-(2-Methoxyphenoxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h]quinolin-3-yl)propyl]piperazine;
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(1H-pyrrolo[3,2-h] quinolin-3-yl)propyl]piperazine;
1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;

20 1-[2-(1,4-Benzodioxan-5-yloxy)phenyl]-4-[3-(1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;
1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Ethoxyphenoxy)phenyl]-4-[3-(5-methyl-1H-indol-3-yl)propyl]piperazine;

25 1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-(Diethylamino)phenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-[2-(2,6-Dimethoxyphenoxy)phenyl]-4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazine;
1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;
1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-chloro-1H-indol-3-yl)propyl]piperazine;

30 1-{2-[3-(Morpholin-4-yl)phenoxy]phenyl}-4-[3-(5-iodo-1H-indol-3-yl)propyl]piperazine;
1-[2-(3-Methoxyphenoxy)phenyl]-4-[3-(7-fluoro-1H-indol-3-yl)propyl]piperazine;
1-(2-Phenoxyphenyl)-4-[3-(5,7-dimethyl-1H-indol-3-yl)propyl]piperazine;
1-[2-(1,3-Benzodioxolan-5-yloxy)phenyl]-4-[3-(7-bromo-1H-indol-3-yl)propyl]piperazine;

1-[2-(3,4,5-Trimethoxyphenoxy)phenyl]-4-[3-(5-bromo-1H-indol-3-yl)propyl]piperazine;

11. A pharmaceutical composition comprising at least one compound of Formula I
- 5 according to any of the claims 1-10 or a pharmaceutically acceptable acid addition salt thereof or prodrug thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.
12. The use of a compound of Formula I according to any of the claims 1-10 or an acid
- 10 addition salt or prodrug thereof for the manufacture of a pharmaceutical preparation for the treatment of the above mentioned disorders.
13. A method for the treatment of affective or neurological diseases and disorders in humans caused by abnormalities in the serotonin system of the central nervous system, comprising
- 15 administrating an effective amount of a compound of Formula I according to any of the claims 1-10;
14. A method according to claim 13 said disease being depression, psychosis, generalised anxiety disorder, panic disorder, and obsessive compulsive disorder, impulse control
- 20 disorder, alcohol abuse, aggression, ischaemia, senile dementia, and social phobia.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00721

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 403/02, C07D 403/14, C07D 413/14, C07D 405/14, C07D 471/04,
 A61K 31/496, A61K 31/5377, A61P 25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9726252 A1 (FMC CORPORATION), 24 July 1997 (24.07.97) --	1-10
X	EP 0376607 A1 (H. LUNDBECK A/S), 4 July 1990 (04.07.90) --	1-14
X	GB 1326833 A (SUMITOMO CHEMICAL COMPANY LIMITED), 15 August 1973 (15.08.73), page 2, line 4 - line 13, the claims --	1-14
X	WO 9514004 A1 (PIERRE FABRE MEDICAMENT), 26 May 1995 (26.05.95) --	1-14

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 March 2001

Date of mailing of the international search report

30-03-2001

Name and mailing address of the ISA

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/BS
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00721

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9902516 A1 (VITA-INVEST, S.A.), 21 January 1999 (21.01.99) --	1-14
X	WO 9424105 A1 (MERCK SHARP & DOHME LIMITED), 27 October 1994 (27.10.94) -- -----	1-14

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/DK00/00721**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 13, 14
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK00/00721

Claims 13,14 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT
Information on patent family members

25/02/01

International application No.	
PCT/DK 00/00721	

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO	9726252	A1	24/07/97	AU	1580997 A 11/08/97
EP	0376607	A1	04/07/90	SE	0376607 T3
				AT	102184 T 15/03/94
				AU	637991 B 17/06/93
				AU	4719889 A 05/07/90
				CA	2006356 A 28/06/90
				DE	68913487 D,T 04/08/94
				DK	169266 B 26/09/94
				DK	645689 A 29/06/90
				ES	2062050 T 16/12/94
				FI	93005 B,C 31/10/94
				FI	896300 D 00/00/00
				GB	8830312 D 00/00/00
				IE	62668 B 22/02/95
				IL	92990 A 24/01/95
				JP	2225460 A 07/09/90
				JP	2895121 B 24/05/99
				NO	174772 B,C 28/03/94
				NO	895281 D 00/00/00
				NZ	231855 A 25/02/92
				PT	92728 A,B 29/06/90
				US	5002948 A 26/03/91
				ZA	8909960 A 28/11/90
GB	1326833	B	15/08/73	AT	310154 B 15/08/73
				BE	771285 A 16/12/71
				CA	965097 A 25/03/75
				CH	564552 A 31/07/75
				DE	2138865 A 22/02/73
				FR	2102282 A,B 07/04/72
				NL	7111186 A 17/02/72
				SE	400285 B,C 20/03/78
				JP	48021948 B 02/07/73
WO	9514004	A1	26/05/95	AU	686278 B 05/02/98
				AU	1070895 A 06/06/95
				CA	2176935 A 26/05/95
				EP	0729455 A 04/09/96
				FR	2712591 A,B 24/05/95
				JP	9505072 T 20/05/97
				NZ	276444 A 26/02/98
				US	5726177 A 10/03/98
WO	9902516	A1	21/01/99	AU	8111398 A 08/02/99
				BR	9810557 A 08/08/00
				CN	1265106 T 30/08/00
				EP	1008594 A 14/06/00
				ES	1037436 U,Y 01/03/98
				ES	2128266 A,B 01/05/99
				PL	337930 A 11/09/00
				SK	272000 A 11/07/00

INTERNATIONAL SEARCH REPORT

Information on patent family members

25/02/01

International application No.

PCT/DK 00/00721

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9424105 A1	27/10/94	AU 6435594 A GB 9307831 D US 5814644 A GB 9316274 D	08/11/94 00/00/00 29/09/98 00/00/00